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The molecular basis of the skipping of constitutive exons in many messenger RNAs is not fully understood. A well-
studied example is exon 9 of the human cystic fibrosis transmembrane conductance regulator gene (CFTR), in
which an abbreviated polypyrimidine tract between the branch point A and the 3′ splice site is associated with
increased exon skipping and disease. However, many exons, both in CFTR and in other genes and have short
polypyrimidine tracts in their 3′ splice sites, yet they are not skipped. Inspection of the 5′ splice sites immediately
up- and downstream of exon 9 revealed deviations from consensus sequence, so we hypothesized that this exon
may be inherently vulnerable to skipping. To test this idea, we constructed a CFTR minigene and replicated exon
9 skipping associated with the length of the polypyrimidine tract upstream of exon 9. We then mutated the flanking
5′ splice sites and determined the effect on exon skipping. Conversion of the upstream 5′ splice site to consensus
by replacing a pyrimidine at position +3 with a purine resulted in increased exon skipping. In contrast, conversion
of the downstream 5′ splice site to consensus by insertion of an adenine at position +4 resulted in a substantial
reduction in exon 9 skipping, regardless of whether the upstream 5′ splice site was consensus or not. These results
suggested that the native downstream 5′ splice site plays an important role in CFTR exon 9 skipping, a hypothesis
that was supported by data from sheep and mouse genomes. Although CFTR exon 9 in sheep is preceded by a
long polypyrimidine tract (Y14), it skips exon 9 in vivo and has a nonconsensus downstream 5
′ splice site identical
to that in humans. On the other hand, CFTR exon 9 in mice is preceded by a short polypyrimidine tract (Y5) but
is not skipped in vivo. Its downstream 5′ splice site differs from that in humans by a 2-nt insertion, which, when
introduced into the human CFTR minigene, abolished exon 9 skipping. Taken together, these observations place
renewed emphasis on deviations at 5′ splice sites in nucleotides other than the invariant GT, particularly when such
changes are found in conjunction with other altered splicing sequences, such as a shortened polypyrimidine tract.
Thus, careful inspection of entire 5′ splice sites may identify constitutive exons that are vulnerable to skipping.
Introduction
Alternative splicing, defined as regulated and produc-
tive variation in patterns of splice-site utilization, in-
creases the diversity of mRNAs and proteins expressed
in the cell (Black 2000; Graveley 2001). Consequences
for mRNA commonly include skipping or inclusion of
one or more exons, substitution of alternate exons, and
deletion or incorporation of a short block of extra cod-
ing sequence adjacent to a constitutive exon. Although
much alternative splicing is regulated and purposeful,
constitutive exons can also occasionally be skipped be-
cause of suboptimal splice sites. Exon 9 of the cystic
fibrosis transmembrane conductance regulator gene
(CFTR [MIM 602421]) is missing in a fraction of CFTR
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transcripts in nearly all individuals (Chu et al. 1991,
1992, 1993). CFTR mRNAs missing exon 9 encoded a
protein that was misfolded and nonfunctional (Delaney
et al. 1993; Strong et al. 1993), suggesting that skipping
of this exon may be a case of nonproductive, rather than
purposeful, alternative splicing. The degree of CFTR
exon 9 skipping is inversely correlated with the length
of a polymorphic polythymidine tract upstream of the
exon. Transcripts derived from genes that carry five thy-
midines (5T) at this locus have high levels of exon 9
skipping, whereas those with seven or nine thymidines
(7T and 9T, respectively) have successively lower levels
of skipping (Chu et al. 1993). The 5T variant can have
a profound effect on splicing, as is illustrated by the
absence of exon 9 in as many as 95% of CFTR tran-
scripts in respiratory epithelia of 5T homozygotes (Chu
et al. 1992). Approximately 10% of individuals world-
wide carry the 5T variant (Kiesewetter et al. 1993),
which is of clinical importance because it is associated
with congenital bilateral absence of the vas deferens
(CBAVD [MIM 277180]), a form of male infertility (Kie-
sewetter et al. 1993; Osborne et al. 1994; Chillo´n et al.
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1995; Jarvi et al. 1995; Zielenski et al. 1995). Penetrance
of the 5T allele for the CBAVD phenotype is variable
and has been estimated to be 0.6 (Zielenski et al. 1995).
Interestingly, rare 5T homozygotes have been reported
with a cystic fibrosis phenotype (CF [MIM 219700])
(Noone et al. 2000), suggesting that 5T is a partially
penetrant disease-causing allele for CF as well.
Several sequence elements in addition to the poly-
thymidine tract appear to contribute to exon 9 skipping.
It has been proposed that longer alleles of a polymorphic
tract of TG repeats immediately upstream of the poly-
thymidine tract exacerbate exon 9 skipping (Cuppens
et al. 1998; Niksic et al. 1999). Indeed, a protein that
binds this TG tract has been identified and shown to
modulate exon 9 splicing efficiency (Buratti and Baralle
2001; Buratti et al. 2001). A 6-bp splicing enhancer and
a 10-bp silencer within exon 9, as well as a silencer
of unknown length in intron 9, have also been iden-
tified (Pagani et al. 2000). Overexpression of a variety
of cellular and viral splicing factors has been shown to
increase exon 9 skipping in transcripts derived from
minigene constructs (Nissim-Rafinia et al. 2000; Pagani
et al. 2000). The overexpression of one particular viral
factor, ORF3, actually decreases exon 9 skipping, al-
though the mechanism responsible for this effect is un-
known (Nissim-Rafinia et al. 2000). These studies sup-
port a model in which splicing of exon 9 is subject to
a number of sequence elements within and near the exon
and to their interactions with trans-acting factors in the
splicing machinery.
A fundamental group of cis-acting sequences that are
known to influence splicing—and that heretofore have
not been thoroughly studied with respect to CFTR exon
9—are the 5′ splice sites flanking the exon. Inspection
of the 5′ splice sites upstream and downstream of CFTR
exon 9 suggested that they may be particularly relevant
in this case, since neither conforms to consensus. Using
a minigene construct, we show that mutating each of
the 5′ splice sites to conform to consensus has opposite
effects upon exon 9 splicing. Interestingly, exon skip-
ping caused by the short (5T) upstream polythymidine
tract can be eliminated by conforming the downstream
5′ splice site to consensus. A cross-species comparison
of these splice-site utilizations andCFTR exon 9 splicing
efficiency in vivo supported conclusions derived from
the minigene studies. Taken together, these observations
point to the importance in exon inclusion of the entire
5′ splice-site sequence.
Material and Methods
Construction of Minigene
Genomic DNA from control samples carrying 5T and
9T alleles were amplified using the following oligonu-
cleotides: ex8f, 5′-GACTCTAGAACATTGGAATAT-
AACTTAACG-3′; ex8r3, 5′-GACGCGGCCGCGTGA-
GTGATCCTCC-3′; ex9f, 5′-CAGGCGGCCGCTGA-
TAATGGGCAAATATC-3′; ex9r, 5′-CAGCCGCGG-
CTAGAGTAAATTATCAGTGG-3′; ex10f, 5′-CAGC-
CGCGGCACACTGTATTGTAATTGTC-3′; ex10r, 5′-
CAGCTGCAGTGCCAGGCATAATCCAGG-3′. PCR
was performed on a Perkin Elmer 480 thermal cycler,
using an initial denaturation of 95C for 5 min, followed
by 30 cycles of 95C for 30 s, 55C for 30 s, and 72C
for 30 s and by an extension of 72C for 10 min. Con-
ditions were 20 mM Tris-HCl, 50 mM KCl, 2.5 mM
MgCl2, 1 mM dithiothreitol, 1 U Taq polymerase (all
from Life Technologies), and 200 mM each dNTP (Phar-
macia) per 50 ml reaction. PCR fragments were subclo-
ned into vector pCR2.1 with TA cloning kit (Invitrogen)
and were sequenced to ensure authenticity. The above
oligonucleotides incorporated unique restriction-enzyme
sites that enabled in-frame fusion of the products into
an ornithine-amino-transferase (OAT) cDNA construct
in the pGEM4 vector (Stratagene) (OAT vector kindly
provided by the laboratories of H. Dietz and D. Valle).
Vector and PCR fragments were joined in a four-way
ligation at 12C overnight (T4 ligase [Life Technologies])
and transformed into MAX Efficiency DH5a cells (Life
Technologies), and the resulting clones were checked for
fragment order, orientation, and authenticity, by use of
restriction digestion and sequencing. The OAT-CFTR
fusion minigene was removed from pGEM4 by EcoRI
digestion and was subcloned into mammalian expres-
sion vector pBK-RSV (Stratagene). Two variants were
initially made, one containing (TG)10T9 and the other
(TG)12T5.
Site-Directed Mutagenesis
Site-directed mutagenesis was performed on the
(TG)12T5 minigene construct by use of the Transformer
kit (Clontech), according to the manufacturer’s instruc-
tions. Selection oligonucleotides in multiply mutated
constructs alternated between a unique BsaI site and a
unique BsmBI site: Bsa-Bsm, 5′-CCACCGAGACGCC-
ATTGGGGC-3′, Bsm-Bsa, 5′-TACCCCACCGAGAC-
CCCATTGGGGCCAATACGC-3′. The followingmuta-
genic oligonucleotides were used:3C-2, 5′-CAGCCTT-
CTGGGAGGAGGTDAGAATTTTTAAAAAATTGTT-
TGCTC-3′, where ; int9donr, 5′-CAGGCAA-D ( C
GGTRAGTTCTTTTGTTCTTCAC-3′, where orR p A
G; and int9d-CT, 5′-GGAGCAGGCAAGGTACTGTT-
CTTTTGTTCTTCAC-3′. Mutated minigenes were ver-
ified by sequencing, grown to bulk and isolated with a
Maxiprep kit (Qiagen).
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Cell Culture, Transfections, and Isolation of RNA
Human embryonic kidney 293 cells (HEK293 [Amer-
ican Type Culture Collection]) were grown in Eagle’s
minimal essential medium supplemented with 10% fetal
bovine serum (both from Biofluids) and 1% penicillin/
streptomycin (Life Technologies), in 5% CO2 at 37C in
T25 flasks (Falcon). Cells were trypsinized (Biofluids)
and transferred to six-well plates (Falcon), were allowed
to adhere for 124 h, and were then transfected with 3
mg plasmid and 10 ml Lipofectin inOptiMEM (both from
Life Technologies), according to the manufacturer’s in-
structions. Transfections were terminated at 8 h with
serum-containing growth media, and cells were allowed
to continue growing until 24 h after transfection, at
which time RNA was harvested with RNAzol B
(TelTest), according to the manufacturer’s instructions,
and was quantified with at least three readings on
GeneQuant RNA/DNA Calculator (Pharmacia).
RT-PCR and Analysis by Capillary Electrophoresis
cDNA was synthesized from 5 mg RNA, using oligo-
dT (Roche) and SuperScript II reverse transcriptase (Life
Technologies), according to the manufacturer’s instruc-
tions. cDNA was synthesized for 50 min at 42C, then
shifted to 70C for 15 min to inactivate the RT. One
microliter of cDNA was amplified under the following
conditions: 20mMTris-HCl, 50mMKCl, 1mMMgCl2,
200 mM each dNTP, 1 mM dithiothreitol, 1 U Taq poly-
merase per 50-ml reaction (Life Technologies), by use of
an initial denaturation at 95C for 5 min, followed by
24, 27, 30, or 33 cycles (separate tubes run in parallel)
of 95C for 30 s, 55C for 30 s, and 72C for 30 s and
by an extension of 72C for 7 min. The primer pair used
for RT-PCR was designed to specifically detect only tran-
scripts derived from our minigene: OAT-specific forward
primer E4S, 5′-GTGCTGTCAACCAAGGGC-3′, and
CFTR-specific ex10r labeled with 5′-fluorescein phos-
phoramidite (Glen Research). PCR products were
sized and quantified by use of capillary electrophoresis
on ABI Prism 310 (Applied Biosystems), using peak-
area measurements.
Data Management and Statistical Analysis
Means, standard deviations, and graphs were gener-
ated with Microsoft Excel. Figures were composed using
Microsoft PowerPoint. Statistical analyses were per-
formed using the JMP statistical package, version 3.2.2
(SAS Institute). For each pair and for comparisons be-
tween groups, analysis of variance was performed. P !
was considered significant. Values were corrected for.05
multiple comparisons, using the Bonferroni method.
Isolation of Total RNA from Ovine Tissues
Tissues were snap-frozen in liquid nitrogen in cryo-
tubes (Nunc) and were stored in liquid nitrogen. Tissue
was homogenized in glass homogenizers in 4 M guan-
idinium isothiocyanate (Fluka). Total RNA was isolated
from cesium chloride (BDH Laboratory Supplies) gra-
dients (specific density 1.7 g/cm3) and was resuspended
in 0.1 mM EDTA and 10 mM Tris (pH 7.4).
RT-PCR for Ovine Tissues
CFTR cDNA synthesis was primed with 3′ primer
B2L 5′-GGAAGGCAGCCTATGTGAGA-3′ under oil
at 65C for 10 min. cDNA was generated by use of the
RT Superscript (Life Technologies) at 42C for 1 h.
PCR was then performed with 5′ primer B2R 5′-AGCC-
ATCAATTTACAGACAC-3′ and B2L, under the fol-
lowing conditions: 1 cycle at 94C for 5 min, 30 cycles
of 94C for 1 min and 60C for 1 min, and extension
at 72C for 3 min, followed by a final cycle of extension
at 72C for 5 min.
Southern Blot Analysis of Ovine RT-PCR Products
RT-PCR products were separated on a 1.5% agarose
gel in Tris-borate EDTA. RT-PCR products were trans-
ferred to Hybond-N membranes (Amersham), using
standard methods, and were probed with randomly
primed a32P-labeled ovine CFTR B fragment (U20418:
1019–1914) (Megaprime DNA labeling kit; Amersham),
as described elsewhere (Tebbutt et al. 1995). Quantifi-
cation of exon 9 and exon 9 products was determined
by phosphorimaging (Amersham).
Results
CFTR Minigene Replicates In Vivo Exon Skipping
To investigate cis-acting sequences that affect CFTR
exon 9 splicing, we created aminigene composed of exon
9, flanking intron sequence, and portions of exons 8 and
10 (fig. 1A). The minigene was fused in-frame to an
ornithine aminotransferase cDNA construct driven by a
Rous sarcoma virus promoter. To determine whether the
length of the polythymidine tract affected the splicing of
our minigene construct, we created one 9T and one 5T.
Because it has been suggested that the distance of the
branch point A from exon 9 plays a role in splicing
efficiency (Cuppens et al. 1998), the number of TG re-
peats preceding the polypyrimidine tract in the 3′ splice
site of intron 8 was adjusted (to 12 TGs in the 5T con-
struct and 10 TGs in the 9T construct) such that the
distance from the branch point A to exon 9 in each
construct was constant. The minigenes were transfected
separately into HEK293 cells, and fluorescent RT-PCR
and capillary electrophoresis were performed to deter-
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Figure 1 Exon 9 splicing of a CFTR minigene construct. Exon 9 splicing is dependent on the length of the polypyrimidine tract in
intron 8. A, Diagram of the CFTR minigene. CFTR exons 8, 9, and 10 are fused in-frame to an ornithine aminotransferase (OAT) cDNA
construct. Both exon 9 and exon 9 transcripts are in-frame. Most of the 6.5-kb intron 8 and 10.6-kb intron 9 have been deleted. Note
two polymorphic loci immediately preceding exon 9. Arrows indicate RT-PCR primers; 3′ primer is tagged with the fluorescent label 6-
FAM. B, Capillary electrophoresis trace of a typical RT-PCR, showing the relative proportions of product derived from transcripts lacking
and including exon 9. C, Results from 9T and 5T variants, showing range of exon skipping observed at 24, 27, 30, and 33 cycles (mean
 SD).
mine the relative proportions of exon 9 and exon 9
transcripts derived from each minigene (fig. 1B). Ac-
curate determination of the ratio of 9 to 9 transcripts,
rather than their absolute quantitation, was necessary
in this study. We therefore chose to compare the peak
area of fluorescence generated by each amplicon, since
this represented the number of DNA molecules newly
synthesized by RT-PCR. This technique has been used
by a number of investigators, because it avoids the im-
precision introduced by hybridization-based techniques
(Teng et al. 1997; Cuppens et al. 1998; Nissim-Rafinia
et al. 2000).
To confirm that PCR was in log phase (so that mea-
surements reflected the concentration of starting tem-
plate rather than a distortion due to saturation of the
PCR), we compared the fluorescent signals after 24, 27,
30, and 33 cycles of PCR. There was a minor increase
in the proportion of exon 9 transcripts at greater cycle
numbers, probably because of preferential amplification
of the shorter 9 fragment (fig. 1C). A small fraction of
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Figure 2 Native nonconsensus nucleotide at 3 position of
intron 8 5′ splice site. The nucleotide reduces skipping of exon 9.
A, Diagram of minigene showing the endogenous cytosine at 3
position and the substitutions made. Asterisks (*) indicate nucleo-
tides that conform to consensus (RAG/GTRAG; R p purine). B,
Substitution of consensus purines in the 3 position. The substi-
tution results in a significant increase in exon skipping, compared
with nonconsensus pyrimidines.
transcripts from the 9T minigene were missing exon 9
(mean [SD] 2.8% [1.8] exon 9 transcripts at 30 cycles),
whereas a substantial proportion of transcripts derived
from the 5T minigene were missing exon 9 (mean [SD]
29.0% [9.8] exon 9 transcripts at 30 cycles) (fig. 1C).
Variability in the splicing efficiency of the 5T construct
was due to differences in passage number of theHEK293
cells. The difference between the 9T and 5T constructs
was statistically significant for all cycle numbers studied
( at 27, 30, and 33 cycles; at 24 cycles).P ! .001 P ! .01
Thus, the minigene replicated exon 9 skipping associated
with polypyrimidine tract length seen in vivo (Chu et al.
1993; Mak et al. 1997; Teng et al. 1997). Since we
wished to determine whether sequence alterations in-
creased or decreased exon 9 skipping, we analyzed RT-
PCR products after 30 cycles of amplification from var-
iants of the 5T minigene for subsequent experiments.
Exon 9 Skipping Increases When the Upstream 5′
Splice Site Conforms to Consensus
Inspection of the 5′ splice site upstream of CFTR exon
9 revealed a nonconsensus pyrimidine at the3 position
(fig. 2A), giving the site a Shapiro-Senapathy score (an
indicator of splice-site strength) of 84.3 (of 100) and an
information content of 5.2 bits, according to an infor-
mation-theory–based algorithm (Shapiro and Senapathy
1987; Rogan et al. 1998). Because only 1 in 40 splice
sites contains a cytosine at the 3 position (Clark and
Thanaraj 2002), the coincidence of finding this unusual
splice-site feature adjacent to exon 9 raised the possi-
bility that it contributes to exon 9 skipping. We hy-
pothesized that mutation of the native 3 cytosine to a
consensus adenine would improve splicing of exon 8 to
exon 9 and would reduce exon skipping. Such a change
resulted in a splice-site score of 94.3 and an information
content of 10.0 bits. However, conversion of the site to
consensus resulted in higher, not lower, levels of tran-
scripts missing exon 9 (fig. 2B). Subsequent substitution
of the3 nucleotide with guanine or thymidine revealed
the following pattern. Nonconsensus pyrimidines at this
location have similar splice-site scores, and they spliced
with roughly equal efficiency (mean [SD] for C p
[9.8] exon 9 transcripts, and mean [SD] for29.0%
[12.1]) The presence of either consensusT p 27.1%
purine resulted in higher splice-site scores but also in
higher rates of exon skipping (mean [SD] for A p
[5.5] exon 9 transcripts, and mean [SD] for49.2%
[6.1]). The difference was significant (G p 48.8% P !
by ANOVA). Thus, creation of a consensus upstream.01
5′ splice site did not, in fact, increase splicing of exon 8
to exon 9 but increased splicing of exon 8 to exon 10
instead. This raised a question about the ability of the
downstream 5′ splice site to define exon 9 and to facil-
itate efficient splicing of exon 9 to exon 10. Therefore,
we next turned our attention to this site.
Exon 9 Skipping Decreases Significantly When the
Downstream 5′ Splice Site Conforms to Consensus
Inspection of the 5′ splice site downstream of CFTR
exon 9 revealed that it also deviated from consensus,
and corresponded to a splice-site score of 74.8 and in-
formation content of 5.9 bits. The site could be made
to conform to consensus by the insertion of an adenine
at position 4 (fig. 3A), resulting in a score of 100.0
and in 12.0 bits of information. The creation of this
change in the minigene resulted in a substantial decrease
in exon 9 skipping among exon 9 transcripts (mean
[SD] 1.6% [2.5] vs. 29.0% [9.8]) (fig. 3B). We concluded
that the newly altered downstream 5′ splice site increased
the efficiency with which exon 9 spliced to exon 10, thus
decreasing splicing of exon 8 to exon 10 and resulting
in a reduced proportion of transcripts missing exon 9.
Taken together, these observations suggested that
exon 9 splicing is subject to a balance between the 5′
splice sites up- and downstream of the exon. To deter-
mine the relative contribution of each of the sites to exon
9 skipping, we evaluated splicing efficiency when the3
nucleotide in the upstream site was altered in a minigene
with a consensus downstream site (effectively combining
the two previous experiments). When a nonconsensus T
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Figure 3 Insertion of adenine at position 4 of the down-
stream 5′ splice site. The insertion reduced exon skipping. A, Con-
sensus splice site created by insertion of an adenine at 4 of intron
9. Daggers (†) indicate nucleotides that conform to consensus after
the insertion. B, Effect of combined mutations at both 5′ splice sites.
Experiments from figure 2 were repeated, with the added difference
of an adenine insertion in the intron 9 5′ splice site. Statistical sig-
nificance was calculated by ANOVA with Bonferroni correction.
was introduced to the upstream site in this new con-
struct, splicing was as efficient as with the exon 9 native
nonconsensus C (mean [SD] 2.4% [2.7] vs. 1.6% [2.5]
(fig. 3B). Interestingly, use of a consensus A or G resulted
in a slight increase in skipping, although splicing was
still far more efficient than with the native intron 9 5′
splice site (mean [SD] with A 10.7% [2.6] vs. 49.2%
[5.5], ; mean [SD] with G 6.8% [1.5] vs. 48.9%P ! .001
[6.1], ) (fig. 3B). Minigenes that contained bothP ! .001
a consensus upstream and a consensus downstream 5′
splice site generated transcripts that used cryptic splice
sites in addition to transcripts that simply skipped exon
9. The pattern of aberrant transcripts, which accounted
for 10%–13% of the total product, was reproducible.
Thus, a consensus 5′ splice site downstream of exon 9
reduces exon skipping, whereas a consensus 5′ splice site
upstream increases exon skipping associated with the
abbreviated polypyrimidine tract.
Cross-Species Comparison of Splice Sequences and
Exon 9 Skipping
To substantiate hypotheses derived from the minigene
studies, we performed a comparison of intron 8 and
intron 9 splice-site sequences in humans, mice, and
sheep, and we studied exon 9 splicing in sheep (results
of human and mouse studies had already been reported
elsewhere [Chu et al. 1993; Delaney et al. 1993]). Sheep
have upstream and downstream 5′ splice-site sequences
very similar to those of humans (score of 80.1, with 2.0
bits upstream, and 69.0, with 4.1 bits downstream). Im-
portantly, however, the polypyrimidine tract in the in-
tron 8 3′ splice site is extensive and is not accompanied
by an adjacent poly-TG tract, as it is in humans (fig.
4A). These observations suggested that the exon skip-
ping associated with a brief polythymidine tract and long
TG variants in humans should not be present in sheep.
Nevertheless, RT-PCR analysis of sheep CFTR tran-
scripts from lung, trachea, colon, pancreas, and small
intestine demonstrated that exon 9 is skipped in all sheep
tissues studied (fig. 4B), at levels comparable to those
of human 9T variants (see legend to fig. 4).
On the other hand, mouse sequence at the 5′ splice
site upstream of exon 9 is different from those of sheep
and humans and conforms to consensus (91.1, 9.1 bits);
in addition, the only discernible polypyrimidine tract in
the mouse intron 8 3′ splice site is brief, at a distance of
16 bases from the intron/exon junction, and is nonun-
iform (fig. 4A). Yet exon 9 is not skipped in CFTR tran-
scripts from murine epithelia (Delaney et al. 1993). In-
terestingly, the mouse downstream 5′ splice site also
differs from human and sheep but does not conform to
consensus (69.5, 3.8 bits). According to the conclusions
drawn from the minigene studies, however, it should
serve as an adequate splice site and should efficiently
splice exon 9 to exon 10 and reduce skipping. Indeed,
replication of the mouse intron 9 5′ splice site by inser-
tion of a CT dinucleotide in the humanminigene resulted
in a substantial reduction of exon 9 skipping (2.5% [1.9]
exon 9). These data are consistent with the hypothesis
that the exact composition of both 5′ splice sites are
significant determinants of exon 9 splicing efficiency.
Discussion
Sequence elements that influence splicing efficiency have
been identified within and near exon 9, indicating that
splicing of this exon is a complex affair involving mul-
tiple competing signals (Cuppens et al. 1998; Niksic et
al. 1999; Nissim-Rafinia et al. 2000; Pagani et al. 2000;
Buratti and Baralle 2001; Buratti et al. 2001). It has
been shown that the length of the polypyrimidine tract
in intron 8 of the CFTR gene is a primary determinant
of the efficiency of exon 9 splicing (Chu et al. 1991,
1992, 1993). However, even the most efficient variant
of this tract, with 9T, is associated with some degree of
exon 9 skipping (Chu et al. 1993). Our observation that
the 5′ splice site upstream of exon 9 deviates from con-
sensus uniquely among 5′ splice sites of the CFTR gene
led us to propose that this exon is inherently vulnerable
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Figure 4 Cross-species comparison of CFTR exon 9 splice sequences and splicing data. A, Sequence comparison of 5′ and 3′ splice
sites of introns 8 and 9 in humans, sheep, and mice. Consensus sequences for 5′ sites are shown at top; y indicates a pyrimidine, and n
indicates any nucleotide. Underlines indicate polypyrimidine tracts, double underlines indicate nonconsensus pyrimidines. B, RT-PCR of
sheep CFTR RNA, using primers B2R and B2L from several tissues. Proportion of exon 9 transcripts: lung 14.6%, trachea 7%, and
pancreas 9.3%. The 9 product intensities for small intestine and colon were outside the linear range so proportions of 9 could not be
calculated. Sequencing revealed that the 896-bp fragment includes exon 9 and the 716-bp fragment is missing exon 9. C, Insertion of a CT
dinucleotide into the endogenous human intron 9 5′ splice site replicates mouse intron 9 5′ splice site and results in efficient splicing of exon
9 in the minigene.
to skipping and that shorter alleles of the polypyrimidine
tract exacerbate this skipping. To test this concept, we
created a minigene containing only two introns, so the
number and type of splicing events that could occur were
limited. However, only immediately flanking intron se-
quence was used, leaving the possibility that critical
splicing signals deep within the introns would be miss-
ing. For example, others have identified a splicing re-
pressor in intron 9 that may involve intron sequences
not present in our minigene (Pagani et al. 2000). Despite
these limitations, exon 9 skipping correlated with poly-
pyrimidine tract length in the minigene, as it does in
vivo. In addition, we used a cross-species comparison of
splice-site sequences and in vivo splicing data to explore
hypotheses generated by the minigene studies. Remark-
ably, despite an extensive polypyrimidine tract, the sheep
constitutively skipped exon 9 in vivo. This result dem-
onstrates that sheep exon 9 is vulnerable to skipping,
even with an optimal polypyrimidine tract, and supports
the view that sequences elsewhere are responsible for
exon skipping. On the other hand, exon skipping was
absent in the mouse when two strong splice sites and a
very brief polypyrimidine tract were present. Thus, com-
parison of CFTR exon 9 splicing in the sheep and mouse
revealed that exon 9 splicing correlated with splice-site
composition and not with polypyrimidine tract length.
These observations are consistent with the concept that
pervasive exon 9 skipping in humans is due to the un-
usual composition of the flanking 5′ splice sites.
Mutations at splice-site nucleotides other than the
invariant GT-AG can and do significantly alter splicing,
often resulting in disease (Rogan et al. 1998; Ketterling
et al. 1999; Ohno et al. 1999; von Kodolitschet al. 1999;
Bolz et al. 2001; Tzetis et al. 2001; Clark and Thanaraj
2002). Documented mutations in 5′ splice sites are twice
as abundant as those in 3′ splice sites (Clark and Than-
araj 2002). Although mutations per se have not been
documented to alter exon 9 skipping, the above-refer-
Hefferon et al.: 5′ Splice Sites and CFTR Exon 9 Skipping 301
enced works point to the profound effects that subtle
changes of 3 to 6 nucleotides in 5′ splice sites can
have on splicing. Sequence analysis predicted the 5′
splice site upstream of exon 9 to be of low efficiency
(computed according to known algorithms [Shapiro and
Senapathy 1987; Rogan et al. 1998]). Thus, we expected
that mutation of this site to match the consensus se-
quence would improve the efficiency of the site and
would increase exon 9 inclusion. It was therefore sur-
prising that the opposite result was obtained. We con-
sidered the following explanations. First, the specific
changes we introduced to the upstream site may have
reduced, rather than increased, its use because of the
sequence context of the region surrounding the exon
8–intron 8 junction. For example, it has been shown
that introns tend to favor a G at the3 position, rather
than an A, in GC-rich regions of the genome (Clark and
Thanaraj 2002). However, the nucleotide content
(∼36% GC) of this region of CFTR is similar to that
of the gene as a whole. A second possibility is that the
3C in the upstream site alters splicing efficiency in our
minigene system but would not cause the same splicing
changes in vivo. We believe that the occurrence of this
unusual splice-site feature upstream of a frequently
skipped exon that significantly increases that exon’s in-
clusion (at least in our minigene) seems unlikely to have
arisen by chance. Keeping in mind the speculative nature
of extrapolating experimental results to in vivo phe-
nomena or evolutionary history, we believe it is possible
that the unusual nucleotide in the upstream site was a
mutation that was retained because of its tendency to
include an otherwise frequently skipped exon. Answer-
ing this question will require a more detailed cross-spe-
cies analysis.
A third possibility requires a consideration of exon
definition. Exon definition proposes that the splice sites
immediately flanking an exon influence one another,
through protein-bridging interactions, and that a change
in one can alter binding at the other, thereby changing
the efficiency with which the exon is recognized (Berget
1995). Indeed, a 5′ splice site that conforms to consensus
is likely to bind U1snRNP more strongly and is capable
of enhancing the binding of the essential splicing factor
U2AF65 to a weak polypyrimidine tract at the upstream
3′ splice site (Hoffman and Grabowski 1992). It is there-
fore plausible that the increased inclusion of exon 9 that
we observed when the downstream 5′ splice sitematched
consensus was due to enhanced exon definition. Finally,
changes made to the upstream 5′ splice site may have
increased its utility as a splice donor, as we predicted;
however, in the context of a weak 3′ site preceding exon
9 (because of the 5T allele), it spliced with greater ef-
ficiency to exon 10 instead. This would imply that the
two 5′ splice sites compete for splicing to exon 10 and
that the degree to which exon 9 is included or skipped
is a result of the balance achieved by these (and other)
splicing signals. There is ample evidence in the literature
that the efficiency with which an exon is included is, in
part, a result of the balance of neighboring splice sites
(Dirksen et al. 1995; Zandberg et al. 1995; Chen and
Helfman 1999). Our observation that creation of a con-
sensus upstream 5′ splice site resulted in higher levels
of exon skipping, even after the downstream 5′ splice
site was mutated to conform to consensus, supports the
balance concept. If the changes in the downstream 5′
splice site improved exon definition, then improvement
in the upstream 5′ site should have increased, rather than
decreased, exon 8 to exon 9 splicing. Thus, we favor a
model of exon 9 splicing in which a precarious balance
is struck between the upstream and downstream 5′ sites
for splicing to exon 10. Variation in other sequence
elements (such as the polypyrimidine tract and the var-
ious regulatory elements identified by Pagani et al.) tip
this balance in favor of exon inclusion or exclusion.
If all the sequence elements thus far identified as af-
fecting exon 9 splicing efficiency are utilized in vivo,
then the splicing of exon 9 appears to be a complex
event. Whether this complexity arose as a compensation
for unfavorable splice-site composition or to facilitate
regulation of CFTR transcripts is a subject for future
study. Our results emphasize the importance that splice-
site nucleotides other than GT-AG can play in making
a constitutive, functionally important exon susceptible
to being skipped. Finally, these data suggest that thor-
ough inspection of intron/exon junctions in other genes
for the presence of unusual splice sites may help to iden-
tify other exons vulnerable to skipping.
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